Scott Hane, MD
Family Medicine · Andover, KSNPI 1780611442
Payments from drug & device makers
Across 35 payments — averaging $13.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$96
- Boehringer Ingelheim$54
- Novo Nordisk$46
- Lilly USA, LLC$46
- Takeda Pharmaceuticals U.S.A., Inc.$42
- Pfizer$33
- plus $163 from 10 others
What the payments were for
- Food & beverage$45294%
- Education$286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 7 | $96 |
| Boehringer Ingelheim | 4 | $54 |
| Novo Nordisk | 3 | $46 |
| Lilly USA, LLC | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Pfizer | 3 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Tris Pharma Inc | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$480 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $137,314 |
| OzempicSemaglutide | 108 | $96,887 |
| EliquisApixaban | 82 | $84,216 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $68,984 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 65 | $62,154 |
| TrulicityDulaglutide | 55 | $56,713 |
| Xigduo XrDapaglifloz Propaned/Metformin | 41 | $23,625 |
| XareltoRivaroxaban | 25 | $20,900 |
| MyrbetriqMirabegron | 31 | $19,791 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $18,664 |
| JardianceEmpagliflozin | 13 | $14,455 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,193 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,351 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,301 |
| FarxigaDapagliflozin Propanediol | 12 | $9,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $46 | $194,027190 claims |
| Novo NordiskOzempic | $46 | $96,887108 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $13 | $91,657140 claims |
| PfizerEliquis, Premarin | $33 | $86,69696 claims |
| MerckJanumet Xr, Januvia | $12 | $27,44833 claims |
| Johnson & JohnsonXarelto | $24 | $20,90025 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $54 | $20,70526 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $19,79131 claims |
| AstraZenecaFarxiga | $12 | $9,15712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Andover
- Paula WorleyAndover$68K
- Lindsay LandersAndover$38K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.